Starling Oncology (STLNW) Common Equity (2019 - 2026)

Starling Oncology (STLNW) has reported Common Equity for 8 consecutive years, with -$24.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 177.28% year-over-year to -$24.9 million; the trailing twelve-month figure through Jun 2026 stood at -$24.9 million (down 177.28% YoY), and the FY2025 full-year result was -$15.7 million, down 538.01% from the prior year.
• Common Equity eased to -$24.9 million in Q2 2026 per STLNW's latest filing, from -$16.3 million in the prior quarter.
• Across five years, Common Equity topped out at $132.0 million in Q1 2022 and bottomed at -$24.9 million in Q2 2026.
• Historically, Common Equity has averaged $46.4 million across 5 years, with a median of $35.3 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Common Equity jumped 179.98% in 2022, then slumped 538.01% in 2025.
• Over 5 years, Common Equity stood at $123.2 million in 2022, then slumped by 53.7% to $57.0 million in 2023, then tumbled by 93.71% to $3.6 million in 2024, then plunged by 538.01% to -$15.7 million in 2025, then plunged by 58.49% to -$24.9 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$24.9 million, -$16.3 million, and -$15.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.